Isomorphic Labs, a company that emerged from Google's DeepMind, has successfully secured $600 million in funding led by Thrive Capital, with contributions from GV and Alphabet. This funding will bolster the development of its AI drug design engine and aid in bringing drugs to clinical trials. Founded by Demis Hassabis, the company aims to expand its research team with this capital. Their previous partnerships with pharmaceutical companies may generate significant milestone payments, and the team behind their technology recently received a Nobel Prize for their contributions to AI-driven drug discovery.
Isomorphic Labs, the AI drug discovery platform that spun out of Google's DeepMind in 2021, has raised $600 million to enhance its AI capabilities.
Founded by DeepMind's Demis Hassabis, Isomorphic Labs plans to utilize its recent capital to accelerate drug development and attract top research talent.
Collection
[
|
...
]